HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

Amneal to buy a biosimilar company; Samsung Bio workers protest
DealsEndpoints News ↗
Amneal to buy a biosimilar company; Samsung Bio workers protest
Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals t…
Apr 23, 2026
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
DealsBriefing
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
Apr 22, 2026
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
DealsFierceBiotech ↗
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
Apr 21, 2026
Asahi Kasei acquires German company Aicuris
DealsPharmaceutical Technology ↗
Asahi Kasei acquires German company Aicuris
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.…
Apr 21, 2026
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
DealsEndpoints News ↗
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in ce…
Apr 20, 2026
Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform
Deals
Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform
Lilly’s $3.25 billion upfront acquisition of Kelonia Therapeutics signals a bold move into in‑vivo CAR‑T techn…
Apr 20, 2026
← Newer Page 9 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.